US Bancorp DE reduced its stake in shares of Iqvia Holdings Inc (NYSE:IQV) by 5.2% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 10,722 shares of the medical research company’s stock after selling 583 shares during the quarter. US Bancorp DE’s holdings in Iqvia were worth $1,392,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. Carillon Tower Advisers Inc. raised its holdings in shares of Iqvia by 9.2% during the 2nd quarter. Carillon Tower Advisers Inc. now owns 258,241 shares of the medical research company’s stock valued at $25,777,000 after buying an additional 21,846 shares during the period. Barings LLC raised its holdings in shares of Iqvia by 74.1% during the 3rd quarter. Barings LLC now owns 18,962 shares of the medical research company’s stock valued at $2,460,000 after buying an additional 8,070 shares during the period. Northern Trust Corp raised its holdings in shares of Iqvia by 7.0% during the 2nd quarter. Northern Trust Corp now owns 1,877,470 shares of the medical research company’s stock valued at $187,408,000 after buying an additional 122,260 shares during the period. Redpoint Investment Management Pty Ltd raised its holdings in shares of Iqvia by 25.0% during the 2nd quarter. Redpoint Investment Management Pty Ltd now owns 13,657 shares of the medical research company’s stock valued at $1,363,000 after buying an additional 2,732 shares during the period. Finally, Oliver Luxxe Assets LLC purchased a new stake in shares of Iqvia during the 3rd quarter valued at about $739,000. Institutional investors and hedge funds own 93.71% of the company’s stock.

Shares of NYSE IQV opened at $115.44 on Tuesday. Iqvia Holdings Inc has a twelve month low of $91.57 and a twelve month high of $135.48. The company has a quick ratio of 1.09, a current ratio of 1.09 and a debt-to-equity ratio of 1.41. The company has a market capitalization of $24.15 billion, a PE ratio of 26.48, a PEG ratio of 1.71 and a beta of 0.81.

Iqvia (NYSE:IQV) last issued its quarterly earnings results on Monday, October 22nd. The medical research company reported $1.42 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.39 by $0.03. Iqvia had a return on equity of 13.69% and a net margin of 12.29%. The business had revenue of $2.59 billion during the quarter, compared to the consensus estimate of $2.58 billion. The firm’s revenue for the quarter was up 5.2% compared to the same quarter last year. On average, equities analysts forecast that Iqvia Holdings Inc will post 5.13 EPS for the current year.

In other Iqvia news, insider Kevin C. Knightly sold 9,216 shares of the business’s stock in a transaction on Friday, September 7th. The stock was sold at an average price of $126.46, for a total transaction of $1,165,455.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director John G. Danhakl sold 370,470 shares of the business’s stock in a transaction on Wednesday, September 12th. The stock was sold at an average price of $124.83, for a total value of $46,245,770.10. The disclosure for this sale can be found here. Insiders have sold a total of 601,586 shares of company stock valued at $75,510,422 in the last 90 days. Insiders own 6.00% of the company’s stock.

Several research firms have issued reports on IQV. Zacks Investment Research downgraded Iqvia from a “buy” rating to a “hold” rating in a report on Monday, August 20th. Raymond James lifted their price objective on Iqvia from $136.00 to $145.00 and gave the stock a “strong-buy” rating in a report on Friday, August 31st. Robert W. Baird lifted their price objective on Iqvia from $143.00 to $146.00 and gave the stock an “outperform” rating in a report on Tuesday, October 2nd. Mizuho set a $120.00 price objective on Iqvia and gave the stock a “hold” rating in a report on Monday, August 6th. Finally, UBS Group began coverage on Iqvia in a report on Tuesday, October 9th. They set a “buy” rating on the stock. Five research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $133.53.

COPYRIGHT VIOLATION WARNING: “Iqvia Holdings Inc (IQV) Shares Sold by US Bancorp DE” was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another website, it was stolen and reposted in violation of U.S. and international copyright and trademark legislation. The original version of this piece can be viewed at https://www.dailypolitical.com/2018/11/20/iqvia-holdings-inc-iqv-shares-sold-by-us-bancorp-de.html.

Iqvia Profile

IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.

Read More: Swap

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.